



Pharmaids Pharmaceuticals Limited

Date: 27-12-2024

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI (LODR) Regulations, 2015')

Pursuant to Regulation 30 and Regulation 30A of SEBI (LODR) Regulations, 2015 read with Clause 5A of Para A of Part A of Schedule III of the SEBI Listing Regulations, the Company has been intimated today that Dr. Shankarappa Nagaraja Vinaya Babu, Chairman and Non-Executive & Non-Independent Director of the Company (hereinafter referred to as 'Acquirer') has entered into a Share Purchase Agreement on December 27, 2024 with Mr. Govindaraja Setty Srinivasa Mithra and Ms. Irakasandra Colony Gangadhar Megha (hereinafter referred to as 'Sellers') under which the Acquirer proposes to acquire 3,27,085 equity shares representing 0.93% of the paid-up share capital of our Company at INR 35/- each equity share amounting to total consideration of INR 1,14,47,975/- (Indian Rupees One Crore Fourteen Lakhs Forty Seven Thousand Nine Hundred & Seventy Five Only).

Further, the details required in terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith as Annexure I.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)



Disclosure under clause (5A) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015:-

S. N	Particulars	Details
a.	If listed entity is a party to the agreement	Not Applicable
b.	If listed entity is not a party to the agreement	
i.	Name of the party entering into such an agreement and the relationship with the listed entity	Dr. Shankarappa Nagaraja Vinaya Babu, Chairman and Non-Executive & Non-Independent Director of our Company is holding 70,20,854 equity shares representing 19.91% of the paid up share capital of our company has entered into the Share Purchase Agreement ('SPA') with sellers, for a purchase of 3,27,085 equity shares representing 0.93% of the total paid up share capital of the Company.
ii	Details of the counterparties to the agreement (including name and relationship with the listed entity)	Mr. Govindaraja Setty Srinivasa Mithra and Ms.Irakasandra Colony Gangadhar Megha (Existing Public Shareholders) are the sellers, selling 3,27,085 equity shares representing 0.93% of the paid-up share capital of our Company to Dr. Shankarappa Nagaraja Vinaya Babu, through the Share Purchase Agreement entered on December 27, 2024 Sellers do not have any relationship with our Company on the date of entering into SPA. The Counterparties to the Agreement acting as sellers are: a. Govindaraja Setty Srinivasa Mithra b. Irakasandra Colony Gangadhar Megha
iii	Date of entering into the agreement	December 27, 2024
c.	Purpose of entering into the agreement	The Acquirer has entered into the SPA with the Sellers for acquisition of shares of the Company.
d.	Shareholding, if any, in the entity with whom the agreement is executed	Not Applicable
e.	Significant terms of the agreement	The SPA is entered between Acquirer and Sellers under which the Acquirer agrees to acquire, and Sellers agrees to sale 3,27,085 equity shares representing 0.93% of the paid-up share capital of our Company.



Pharmaids Pharmaceuticals Limited

		<p>The brief terms are mentioned below-</p> <ol style="list-style-type: none">1. Date of entering SPA – December 27, 20242. Consideration - INR 1,14,47,975/- (Indian Rupees One Crore Fourteen Lakhs Forty Seven Thousand Nine Hundred & Seventy Five Only)3. Sale Shares - 3,27,085 equity shares representing 0.93% of the paid-up share capital of our Company.4. Consequent to execution of the SPA, the Acquirer has given an open offer to the public shareholders of our company in terms of Regulation 5 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
f.	Extent and the Nature of impact on management or control of the listed entity	<p>Pursuant to the completion of open offer, the Acquirer will be classified as the Promoters/Promoter Group of our Company and few existing members of promoter and promoter group will be classified into public category, in terms of the Regulation 31A (10) of SEBI(LODR) Regulations, 2015.</p> <p>Thus, the Acquirer will acquire control over the management and affairs of the Company.</p>
g.	Details and Quantification of the restriction or liability imposed upon the listed entity	Nil
h.	Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship	No, the Acquirer and sellers are not related to promoter/promoter group/group companies in any manner.
i.	Whether the said transaction falls under within related party transactions? If yes, whether the same is done at arm's length	No, the transaction would not fall within related party transactions.
j.	In case of issuance of shares to the parties, details of issue price, class of shares issued.	Not Applicable
k.	Any other disclosures related to such agreements, viz details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreement etc	Not Applicable

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA

Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com



Pharmaids Pharmaceuticals Limited

I.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange: i. Name of the parties to the agreement ii. Nature of the agreement iii. Date of execution of the agreement iv. Details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier) v. Reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier)	Not Applicable
-----------	---	----------------

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)